Capricor Therapeutics(CAPR) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update ● Announced intent to file a biologics license application (BLA) for deramiocel to treat all patients with DMD-cardiomyopathy ● Rolling BLA submission initiated in October 2024 with full submission expected by year-end 2024 ● Company anticipates potential PDUFA date in second half of 2025 ● Announced signing of binding term sheet with Nippon Shinyaku for European expansion and commercialization of d ...